BIOCRYST PHARMACEUTICALS INC
Federal contract awards won by BIOCRYST PHARMACEUTICALS INC (UEI MGXADJ6SCLJ5), 2013–2026 — public record from USAspending.
Showing awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
12
awards
$198,265,727
total value
2
agencies
Agencies buying from BIOCRYST PHARMACEUTICALS INC
What BIOCRYST PHARMACEUTICALS INC sells
Awards
BPA FOR ORLADEYO AND RAPIVAB
Department of Veterans Affairs · $93,000,000 · Jun 3, 2026
PHARM - ORLADEYO
Department of Veterans Affairs · $360,000 · Oct 1, 2025
BULK ORDER ORLADEYO FOR VETERAN CARE.
Department of Veterans Affairs · $382,301 · Sep 9, 2025
BULK ORLADEYO PHARMACEUTICAL
Department of Veterans Affairs · $394,853 · Mar 12, 2025
BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).
Department of Veterans Affairs · $379,939 · Oct 1, 2024
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Department of Health and Human Services · $13,877,674 · Sep 30, 2024
BEROTRALSTAT HCL 150MG CAP,ORAL TRADE NAME: ORLADEYO 150MG CAP
Department of Veterans Affairs · $374,626 · Sep 9, 2024
BULK ORDER ORLADEYO
Department of Veterans Affairs · $385,448 · Mar 12, 2024
BEROTRALSTAT HCL 150MG CAP,ORAL BULK, 72769-0101-01
Department of Veterans Affairs · $368,683 · Jun 1, 2022
COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.
Department of Health and Human Services · $6,326,480 · Sep 1, 2020
PERAMIVIR, RAPIVAB FLU TREATMENT
Department of Health and Human Services · $34,660,000 · Sep 1, 2018
IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017
Department of Health and Human Services · $47,755,723 · Sep 16, 2013
Researching this competitor? BidCatch doesn't just show you what they won — it sends you the open bids in your trade every morning, before they're awarded. Free for 14 days, then $49.99/month.
Search open bids